Response to "Critical Analysis of Apixaban Dose Adjustment Criteria"

Clin Appl Thromb Hemost. 2022 Jan-Dec:28:10760296221078841. doi: 10.1177/10760296221078841.

Authors

Stephen R Mandt¹, Puneet Gaitonde², Antoinette Ajavon-Hartmann¹, Christian Klem¹, Anthony Chan², Arnaud Bastien¹

Affiliations

¹ 480678Bristol Myers Squibb, Inc., Lawrence Township, NJ, USA.
² 2253Pfizer, Inc., New York, NY, USA.

No abstract available

Publication types

Letter
Comment

MeSH terms

Humans
Pyrazoles*
Pyridones*

Substances

Pyrazoles
Pyridones
apixaban